Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H28ClN3O2S |
| Molecular Weight | 446.005 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(Cl)C=C24)CC1
InChI
InChIKey=AIUHRQHVWSUTGJ-UHFFFAOYSA-N
InChI=1S/C23H28ClN3O2S/c1-18(28)29-16-15-26-13-11-25(12-14-26)9-4-10-27-20-5-2-3-6-22(20)30-23-8-7-19(24)17-21(23)27/h2-3,5-8,17H,4,9-16H2,1H3
| Molecular Formula | C23H28ClN3O2S |
| Molecular Weight | 446.005 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 33 - 60 |
Disc. AE: Parkinsonism... AEs leading to discontinuation/dose reduction: Parkinsonism (10%) Sources: |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 39 - 69 |
Disc. AE: Parkinsonism... AEs leading to discontinuation/dose reduction: Parkinsonism (20%) Sources: |
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, 44 - 70 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Parkinsonism | 10% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 33 - 60 |
| Parkinsonism | 20% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 39 - 69 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tetrabenazine in the treatment of Huntington's disease. | 2007 |
|
| A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. | 1974-01-26 |
|
| Persistent tardive dyskinesia. | 1971-09-04 |
|
| Acetophenazine (Tindal) and thiopropazate (Dartal) in ambulatory psychoneurotic patients. | 1961-10 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:28 GMT 2025
by
admin
on
Mon Mar 31 18:00:28 GMT 2025
|
| Record UNII |
0JFY081Q2X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
N05AB05
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
||
|
WHO-VATC |
QN05AB05
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
||
|
NCI_THESAURUS |
C740
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3401
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
DTXSID6023654
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
C100194
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
SUB10982MIG
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
100000082146
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
38133
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | RxNorm | ||
|
C152590
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697851
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
201-513-4
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
59119
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
2634
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
84-06-0
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
m10779
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | Merck Index | ||
|
742
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
6762
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
0JFY081Q2X
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
DB13557
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY | |||
|
Thiopropazate
Created by
admin on Mon Mar 31 18:00:28 GMT 2025 , Edited by admin on Mon Mar 31 18:00:28 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |